Form 4: Teva Pharmaceutical Industries Director, Gerald Lieberman, Acquires Restricted Share Units
SEC Form 4 Filing
Director Gerald Lieberman acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.
Summary
- On June 6, 2024, Gerald M. Lieberman, a director of Teva Pharmaceutical Industries Ltd., acquired 9,632 restricted share units.
- These restricted share units represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.
- The restricted share units were granted on June 6, 2024, and will vest on June 6, 2025.
- Following the transaction, Lieberman beneficially owns 9,632 ordinary shares directly.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
This filing reflects standard executive compensation practices within the pharmaceutical industry, where restricted share units are commonly used to align the interests of directors and shareholders.
Stakeholder Impact
- The acquisition of restricted share units by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Gerald Lieberman acquired 9,632 restricted share units. |
| 06/06/2025 | Vesting date of the restricted share units. |
| 06/10/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.